期刊
JAMA NEUROLOGY
卷 70, 期 3, 页码 390-393出版社
AMER MEDICAL ASSOC
DOI: 10.1001/jamaneurol.2013.668
关键词
-
资金
- German Ministry for Education and Research (Bundesminsterium fur Bildung und Forschung [BMBF])
- German Competence Network Multiple Sclerosis (Krankheitsbezogenes Kompetenznetz Multiple Sklerose) [01GI1002]
- Innovative Medicines Initiative Joint Undertaking [115303]
- European Union's Seventh Framework Programme (Framework Programme 7)
- European Federation of Pharmaceutical Industries and Associations
- Walter-and Ilse-Rose Stiftung
- Eugene Devic European Network (E-rare/EU-FP7)
- German Ministry for Education and Research BMBF [01GM1203A]
Background: Neuromyelitis optica (NMO) is an autoimmune disease of the central nervous system in which aberrant antibody responses to the astrocytic water channel aquaporin 4 have been described. Experimental evidence is emerging that NMO is partly driven by the proinflammatory cytokine interleukin 6 (IL-6), which propagates the survival of disease-specific B cell subclasses, and deviates CD4(+) T helper cell differentiation toward IL-17-producing T helper 17 cells. Tocilizumab is a recombinant humanized monoclonal antibody against the IL-6 receptor approved for treatment of rheumatoid arthritis. Objectives: To study clinical and paraclinical effects of tocilizumab in a patient with NMO. Design: Case report. Setting: Academic neurology department. Patient: A patient with highly active aquaporin 4-seropositive NMO who failed numerous immunosuppressive interventions, including high-dose corticosteroids, mitoxantrone, plasma exchange (PE), rituximab (anti-CD20), and alemtuzumab (anti-CD52), before receiving tocilizumab. Main Outcome Measures: Clinical disability, magnetic resonance imaging, cytokines and transcription factors levels in the cerebrospinal fluid, and peripheral blood mononuclear cells. Results: A patient who continued to accumulate neurological disability and magnetic resonance imaging activity while receiving numerous immunoactive therapies stabilized, and eventually improved clinically and on magnetic resonance metrics after treatment initiation with tocilizumab. Treatment and clinical response correlated with a significant reduction of IL-6 levels in the CSF as well as a diminished expression of signal transducer and activator of transcription 3. Conclusions: Tocilizumab might be effective in NMO, here in a patient not responding to leukocyte depletion. Our findings further support data that implicate IL-6 as a critical molecule in the immunopathogenesis of NMO, and a critical role for T cells in the pathogenesis of this disorder. JAMA Neurol. 2013;70(3):390-393. Published online December 24, 2012. doi:10.1001/jamaneurol.2013.668
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据